Society Testimony

Testimony to FDA on CGM Indication Change

July 21, 2016

Testimony of the Endocrine Society Submitted to the Food and Drug Administration Clinical Chemistry and Clinical Toxicology Devices Panel 

"Finally, patients need guidance on using unverified CGM data safely and effectively. FDA’s approval of this change would enable Dexcom to offer patient support and education on the best ways to use unverified CGM data in real time. It would also allow clinicians to offer cogent advice on how to use the data safely and effectively without verification and for Dexcom to offer appropriate support to clinicians around this important topic. "

arrowRead the Full Testimony

Last Updated:

Policy Communications

Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Journals

The Best of Endocrine Society Journals 2020

Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.

Explore a collection of top articles published in the Endocrine Society journals in 2020, selected on the basis of citations, downloads, and Altmetric score.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!